L01XD03 - Methyl Aminolevulinate |
Not porphyrinogenic |
NP |
Rationale
Insignificant systemic exposure. No phototoxic effects outside the skin application site.
Chemical description
Methyl aminolevulinate is a linear metylated five carbon molecule. After tissue demetylation it constitutes the initial precursor in porphyrin biosynthesis.
Therapeutic characteristics
Methyl aminolevulinate hydrochloride is a derivative of 5-aminolevulinic acid that is applied topically for the treatment of non-hyperkeratotic, non-pigmented actinic keratoses of the face or scalp, and in the treatment of superficial and/or nodular basal cell carcinoma.
Hepatic exposure
Not significant.
Metabolism and pharmacokinetics
Metabolized in situ to phototoxic porphyrins. In-vitro studies of dermal absorption found that the mean cumulative absorption of methyl aminolevulinate through healthy human skin after 24 hours was 0.26% of a dose.
References
- Drug reference publications
- Sweetman SC, editor. Martindale: The complete drug reference. Methyl aminolevulinate Hydrochlorid. Pharmaceutical Press 2009. #2054
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Metvix. #2053
Similar drugs
© NAPOS 2024